Unicancer
Catherine Léger is a seasoned professional in clinical development with extensive experience in oncology. Currently serving as Clinical Program Lead at Unicancer since February 2023, Catherine previously held prominent roles at Servier from 2014 to January 2023, including Global Clinical Development Leader and Global Clinical Project Manager. Prior to Servier, Catherine was a Global Clinical Project Manager at AB Science from 2012 to 2014 and served as Clinical Operations Manager at CEMO S.A. from 2002 to 2012. Early in the career, Catherine worked as Clinical Trial Manager at AXONAL from 1997 to 2002. Educational qualifications include a DESS in Statistical Methods for Agronomic, Agro-food, and Pharmaceutical Industries from the University of Montpellier, as well as specialized training in Therapeutic Innovations in Oncology and Onco-Pharmacology from Gustave Roussy and Institut Curie-Hôpital René Huguenin, respectively.
This person is not in any teams
Unicancer
UNICANCER groups together the 20 French Comprehensive Cancer Centres (FCCCs) which are private, not-for-profit hospitals located across the French territory. FCCCs are dedicated to fighting cancer through a threefold mission of patient care, research and education. They contribute to the public hospital service in accordance with statutory fees, with no additional charge. UNICANCER is one of the largest cancer care and research organisations in Europe. Via its R&D department, it sponsors clinical trials to improve cancer patients’ care and access to innovation, particularly in areas neglected by the pharmaceutical industry. UNICANCER is accredited by the French Ministry of Health and is eligible for public grants. The French Comprehensive Cancer Centres in numbers: • 20 sites located throughout the French territory • 19,000 employees • >135,000 patients hospitalised each year • Approximately 500 active clinical trials • 17% of the patients treated are included in a clinical trial (vs an average of 8.5% of cancer patients in France) • 19 molecular biology platforms certified by the French National Cancer Institute • 7 integrated cancerology research sites (SIRIC) certified by the French NCI (out of 8) • 12 early-phase clinical trial Centres (CLIP²) certified by the French NCI (out of 16) • 5th for global publications in oncology • 32% of French publications in oncology (articles in which FCCCs have participated) UNICANCER sponsors • 76 ongoing clinical trials (2016) • Including 5400 patients (2016) • From 270 investigator sites (2015), • With 20% located in other European countries